Orthofix Medical (OFIX) Research & Development (2010 - 2026)

Orthofix Medical (OFIX) has reported Research & Development for 17 consecutive years, with $15.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development changed 0.06% year-over-year to $15.9 million; the trailing twelve-month figure through Jun 2026 stood at $61.4 million (down 14.47% YoY), and the FY2025 full-year result was $65.8 million, down 10.59% from the prior year.
• Research & Development was $15.9 million for Q2 2026 at Orthofix Medical, up from $15.3 million in the prior quarter.
• The five-year high for Research & Development was $99.2 million in Q2 2023, with the low at -$207.8 million in Q4 2023.
• Historically, Research & Development has averaged $16.7 million across 5 years, with a median of $18.4 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development plunged 310.9% — and 2024, when it surged 109.05%.
• Tracing OFIX's Research & Development over 5 years: stood at -$120.4 million in 2022, then tumbled by 72.52% to -$207.8 million in 2023, then surged by 109.05% to $18.8 million in 2024, then dropped by 18.26% to $15.4 million in 2025, then grew by 3.71% to $15.9 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $15.9 million in Q2 2026, $15.3 million in Q1 2026, and $15.4 million in Q4 2025.